Esmolol contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) No edit summary |
Gerald Chi- (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Esmolol}} | {{Esmolol}} | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}}; {{AK}} | ||
==Contraindications== | ==Contraindications== | ||
| Line 8: | Line 8: | ||
* '''Severe [[sinus bradycardia]]''': May precipitate or worsen [[bradycardia]] resulting in [[cardiogenic shock]] and [[cardiac arrest]] | * '''Severe [[sinus bradycardia]]''': May precipitate or worsen [[bradycardia]] resulting in [[cardiogenic shock]] and [[cardiac arrest]] | ||
* '''[[Heart block]]''' greater than first degree: Second- or third-degree [[atrioventricular block]] may precipitate or worsen [[bradycardia]] resulting in [[cardiogenic shock]] | * '''[[Heart block]]''' greater than first degree: Second- or third-degree [[atrioventricular block]] may precipitate or worsen [[bradycardia]] resulting in [[cardiogenic shock]] and [[cardiac arrest]]. | ||
* '''[[Sick sinus syndrome]]''': May precipitate or worsen [[bradycardia]] resulting in [[cardiogenic shock]] and [[cardiac arrest]] | * '''[[Sick sinus syndrome]]''': May precipitate or worsen [[bradycardia]] resulting in [[cardiogenic shock]] and [[cardiac arrest]] | ||
* '''Decompensated [[heart failure]]''': May worsen [[heart failure]] | * '''Decompensated [[heart failure]]''': May worsen [[heart failure]] | ||
Revision as of 22:52, 20 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]; Abdurahman Khalil, M.D. [3]
Contraindications
BREVIBLOC (Esmolol Hydrochloride) is contraindicated in patients with:
- Severe sinus bradycardia: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest
- Heart block greater than first degree: Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest.
- Sick sinus syndrome: May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest
- Decompensated heart failure: May worsen heart failure
- Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest
- IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil
- Pulmonary hypertension: May precipitate cardiorespiratory compromise.
- Hypersensitivity reactions, including anaphylaxis, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).[1]
References
Adapted from the FDA Package Insert.